Your abstract submission has been received

Print this page

You have submitted the following abstract to the ASRM 2025 Scientific Congress & Expo. Receipt of this notice does not guarantee that your submission was complete or free of errors.

A COMPARISON OF EMBRYO TRANSFER OUTCOMES BETWEEN TRANSGENDER MEN AND CISGENDER WOMEN

Kyle Le, MD[1], Jing Wu, MD, MS[2], Atoosa Ghofranian, M.D.[3], Laura X Zalles, M.D.[4], Kerry S.J. Flannagan, PhD[2], Alan B. Copperman, M.D.[5], Kate Devine, M.D.[6] and Phillip A Romanski, M.D., M.SC.[5], (1)Shady Grove Fertility, Washington, DC, (2)US Fertility, Rockville, MD, (3)Icahn School of Medicine at Mount Sinai, New York, NY, (4)University of Colorado, Denver, CO, (5)Reproductive Medicine Associates of New York, New York, NY, (6)Shady Grove Fertility Center, Rockville, MD

Title:
A COMPARISON OF EMBRYO TRANSFER OUTCOMES BETWEEN TRANSGENDER MEN AND CISGENDER WOMEN

Submitter's E-mail Address:
kylenle@gmail.com

Preferred Presentation Type:
Oral or Poster

Study Type:
Retrospective Cohort Study (includes comparator groups)

Category - Subcategory(ies)s:
Infertility: Outcomes

Funding:
This study received no funding.

References:
Leung et al. Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine. Fertil Steril 2019;112(5):858-65

Amir et al. Ovarian stimulation outcomes among transgender men compared with fertile cisgender women. J Assist Reprod Genet 2020;37:2463-72

* **Submission of an abstract for consideration for presentation implies that the presenting author & associated co-authors have legal and ethical rights to submit and present this work. Plagiarism and submitting work that an author has no rights to, will result in an investigation and penalty.**

* **I verify that I am in compliance with HIPAA standards to protect the privacy of the patients discussed in my presentation(s). I either have received written authorization from the patient, have removed any identifiable images or patient records from my presentation, or my presentation does not pertain to patient treatment.**

Permissions - Prior Publication or Presentation
This abstract contains original work, not published or presented previously at a meeting of another national or international scientific organization prior to this meeting and has not been submitted for publication at the time of this submission.

ACCME Disclosure
Nothing to disclose. No off-label or otherwise non-approved product use.

Did this abstract require approval by a local Institutional Review Board (IRB) or equivalent?
This abstract did not utilize human subjects or any human materials.

Applying for an award

Trainee: Yes

Abstract Category:
All Other Categories

Applied for the In-Training Award for Research

Abstract Text:
OBJECTIVE: Prior studies reporting fertility treatment outcomes among transgender men have focused on oocyte retrieval outcomes, but data on embryo development and subsequent embryo transfer (ET) outcomes in this population are limited.[1-2] The primary objective of this study was to assess pregnancy outcomes following ET among transgender male patients.

MATERIALS AND METHODS: Electronic medical records were searched using natural language processing of 23 key terms (e.g. 'transgender," "trans male") to identify trans men, confirmed by chart review, who presented to a large fertility clinic network between 2005-2023. Trans male patients that underwent IVF and ET during the study period were included. Cisgender female patients with a trans male partner who themselves underwent IVF-ET during the study period were included as a referent group.

The primary outcome was cumulative live birth (CLB) defined as proportion of IVF cycles resulting in at least one live birth from all ETs resulting from that cycle. Secondary outcomes included additional pregnancy and embryo development outcomes. Statistical analysis was performed using generalized linear regression with mixed-effects model controlled for age at retrieval and BMI to compare outcomes between groups. The CLB of each group was estimated via survival analysis with Gray's test for comparison among groups.

RESULTS: There were 15 trans men who underwent 19 IVF cycles and 42 cisgender females who underwent 52 IVF cycles. The primary outcome of CLB was comparable between trans male patients (70%) compared to the cisgender female referent group (70%; RR 1.02 (0.50, 2.06)). Other pregnancy outcomes were also comparable between the trans male and cisgender female groups including live birth per ET (68% vs. 41%; RR 1.66; (0.84, 3.28)). Of the 15 trans male patients, two underwent an ET to their own uterus and the other 13 trans male patients had a cisgender female partner that underwent ET(s). These two trans male patients both had a live birth after the first ET for a CLB of 100%.

Embryo development outcomes were also comparable between trans men and cisgender women including mature oocytes (13.0 vs. 14.3; RR 0.91 (0.70, 1.19)), 2PNs (9.2 vs. 11.2; RR 0.82 (0.61, 1.10)), and usable blastocysts (5.6 vs. 5.3; RR 1.06 (0.72, 1.56)).

In a subgroup of trans male patients, those with a history of testosterone exposure (n=10) had similar CLB (80%) compared to those without a history of testosterone exposure (n=5) (80%; RR 1.02 (0.31, 3.43)).

CONCLUSIONS: Trans male patients that undergo IVF followed by ET have live birth outcomes comparable to cisgender females. Embryo development outcomes among transgender patients were also comparable to the referent group. In a subgroup of trans male patients with prior testosterone exposure, live birth outcomes were similar to those without prior testosterone exposure. While this is the largest cohort of trans male patients reporting ET outcomes, larger

cohorts will be needed to confirm these results.

IMPACT STATEMENT: Embryos transferred from trans men with and without prior testosterone exposure have similar pregnancy, live birth, and CLBs compared to cisgender female individuals.

First Presenting Author

Presenting Author

Kyle Le, MD
Email: kyle.le@sgfertility.com -- Will not be published

Shady Grove Fertility
2021 K St.
Suite 101 & 701
Washington DC 20006
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Kyle Le

CV Upload:

Le_Kyle_CV_2025.4.5.docx

Second Author

Jing Wu, MD, MS
Email: jing.wu@usfertility.com -- Will not be published

US Fertility

Senior Biostatistician
9601 Blackwell Drive, Suite 501
Rockville MD 20850
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Jing Wu, M.D.

Third Author

Atoosa Ghofranian, M.D.
Email: aghofranian@rmany.com -- Will not be published

Icahn School of Medicine at Mount Sinai
Obstetrics, Gynecology, and Reproductive Science
1176 Fifth Ave, Klingenstein Pavilion
9th Floor
New York NY 10029
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Atoosa Ghofranian, M.D.

CV Upload:

CV 2021.pdf

Fourth Author

Laura X Zalles, M.D.
Email: laurazallesmd@gmail.com -- Will not be published

University of Colorado
Obstetrics & Gynecology
8200 E Belleview Ave
#615e
Denver CO 80220-4982
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Laura Zalles, MD

CV Upload:

Laura Zalles CV.docx

Fifth Author

Kerry S.J. Flannagan, PhD
Email: kerry.flannagan@usfertility.com -- Will not be published

US Fertility
9600 Blackwell Road
Rockville MD 20850
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Kerry Flannagan, PhD

Sixth Author

Alan B. Copperman, M.D.
Email: acopperman@rmany.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Avenue
10th Fl.
New York NY 10022-1009
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
Yes

Organization Name	Relationship Type	Who has this Relationship?	
Progyny	Company Officer Relationship Began - Friday, August 25, 2017 Relationship Ended - Thursday, June 1, 2023 Paid Consultant Relationship Began - Relationship Ended - Direct Stockholder Relationship Began - Friday, August 25, 2017 Relationship Ended - Friday,	Self	

	November 1, 2024	

Signature: Alan B Copperman

CV Upload:

Alan B. Copperman M.D. - CV (March 2024).docx

Seventh Author

Kate Devine, M.D.
Email: kate.Devine@sgfertility.com -- Will not be published

Shady Grove Fertility Center
Rockville MD
USA

Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Kathleen M. Devine

Eighth Author

Phillip A Romanski, M.D., M.SC.
Email: phillip.romanski@gmail.com -- Will not be published

Reproductive Medicine Associates of New York
635 Madison Ave 10th Fl

New York NY 10022-1009
USA

Biographical Sketch Phillip Romanski, M.D., M.Sc., is a Reproductive Endocrinology and Infertility physician at RMA of New York in Manhattan and is a faculty member at the National Institutes of Health. He is an expert in family-building including the evaluation and management of female and male infertility, third-party reproduction, and fertility preservation. Dr. Romanski completed his residency in Obstetrics and Gynecology at Harvard Medical School (Brigham and Women's Hospital/Massachusetts General Hospital) and his fellowship in Reproductive Endocrinology and Infertility at the Weill Cornell Medical Center/NewYork-Presbyterian Hospital. Dr. Romanski additionally serves as the Associate Research Director for US Fertility and has authored over 60 peer-reviewed research publications with a particular interest in patients with a history of unsuccessful treatment and patients with diminished ovarian reserve. In recognition of his research contributions, he has received multiple national awards and has subsequently been invited to speak at both national and international conferences to present his work.
Within the past 2 years, have you or your spouse/partner had any potential COI?
No
Signature: Phillip Romanski, M.D.,M.SC.

CV Upload:

Mount Sinai CV.docx

If necessary, you can make changes to your abstract submission until Wednesday, April 30, 2025 at 4:00 pm (EDT).

To access your submission in the future, use the link to your user portal from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to https://asrm.confex.com/asrm/2025/gateway.cgi

You will be prompted to login with your ASRM account prior to accessing the user portal. If you do not yet have an ASRM account, the screen will redirect you to the site where you can register for a new account. When registering for a new ASRM account:

- Please use the email address that is associated with the submission and your first and last name as they appear on the submission when creating this account.
- An ASRM account for login must be completed before you can access the user portal.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

If you would like to submit another abstract, click here.

Tell us what you think of the abstract submission process

Home Page